📣 ADDS Basel 2025  |  Friday, September 12, 2025

Learn more

THERAPEUTIC EXPERTISE

Solutions for Neuromuscular Disorder Research

Existing clinical outcome measures are often inadequate for assessing drug efficacy in neuromuscular disorder (NMD) trials, making the development of novel treatments a challenge in an area where there is a large unmet need for new therapy options. Wearable digital health technologies (DHTs) provide an unprecedented opportunity to directly and objectively assess real-world function to accelerate drug development in NMDs.

Schedule a Meeting Download the Guide

Indications Where DHTs Have Been Included in Clinical Development

  • Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease))
  • Duchenne’s Muscular Dystrophy (DMD)
  • Myotonic Dystrophy
  • Spinal Bulbar Muscular Atrophy (SBMA, or Kenney’s disease)
  • Spinal Muscular Atrophy

Selected Digital Endpoints for Neuromuscular Disorder Research

Physical Activity

  • Moderate to Vigorous Physical Activity (MVPA)
  • Non-Sedentary Time

Gait & Mobility

  • Gait Speed / Cadence
  • Real-World 6-Minute Walk Distance

Upper Limb Function

  • Wrist Activity Counts
  • 6-Minute Peak Activity (Wrist)
  • Specific Upper Limb Movement Metrics

Sleep

  • Wake After Sleep Onset (WASO)
  • Total Sleep Time
  • Sleep Efficiency

Vital Signs

  • Heart Rate / Heart Rate Variability
  • Arrythmia Burden
  • Respiratory Rate
  • Oxygen Saturation
  • Blood Pressure
  • Skin Temperature
Physical Activity
  • Moderate to Vigorous Physical Activity (MVPA)
  • Non-Sedentary Time
Gait & Mobility
  • Gait Speed / Cadence
  • Real-World 6-Minute Walk Distance
Upper Limb Function
  • Wrist Activity Counts
  • 6-Minute Peak Activity (Wrist)
  • Specific Upper Limb Movement Metrics
Sleep
  • Wake After Sleep Onset (WASO)
  • Total Sleep Time
  • Sleep Efficiency
Vital Signs
  • Heart Rate / Heart Rate Variability
  • Arrythmia Burden
  • Respiratory Rate
  • Oxygen Saturation
  • Blood Pressure
  • Skin Temperature

Neuromuscular Disorders Digital Endpoint Guide

To learn more about opportunities with wearable digital health technologies in Neuromuscular Disorder clinical trials, download our full guide.

Download the Guide

Functional Assessments

Many NMDs are characterized by muscle weakness and impairment, severely limiting patients’ activities of daily living and are the focus for drug development efforts. DHTs provide objective and continuous assessment of real-world patient function yielding a means of demonstrating clinical benefit of new therapies, even in long trials and long-term follow-ups. 

Collection of physical function, sleep, and vital sign measures with DHTs not only provide more frequent and sensitive measures for more accurate outcome assessments, but remote data collection with DHTs alleviates the burden of travel to a clinical site, which is a leading barrier to study participation for patients living with NMDs. 

Key Features & Benefits

  • Digital measures applicable for ambulatory and non-ambulatory patients
  • FDA cleared, medical-grade wearables
  • Low-burden, passive, remote data collection and transfer
  • Participant adherence monitoring
View Algorithms and Measures

Digital Health Monthly

Learn more about the latest research using DHTs to capture continuous and objective data related to the motor function of patients with ALS, providing more detailed data on disease progression and treatment efficacy.

Patient-Focused Digital Measures Reports

Regulatory agencies acknowledge the need to improve clinical endpoints for NMD drug development and the potential of DHTs to address this need. 

Access our NMD digital measure reports inspired by the FDA’s Patient-Focused Drug Development (PFDD) initiative, leveraging information from Voice of the Patient summaries to highlight how digital health technologies can help measure symptoms that are meaningful to patients.

Experience in Neurology Trials

62
trials
1,517
sites
44
countries
4,751
participants